Rethinking Madness and Medication: Researcher Discusses Psychiatric Drug Withdrawal and Survivor Movements
New understandings of medication and withdrawal experiences warrant rethinking conceptualizations of health and “madness."
Acknowledging that current depression treatments are failing many people, researchers from Michigan State and MIT have developed a new model for understanding how multiple psychological, biological, social and environmental factors contribute to depression.
Depressed pregnant women need good care. They should not be made to feel guilty for the choices they make concerning their depression or lectured to by those who don’t understand the area or lack compassion for them. In that sense, Andrew Solomon does the public a service by turning his attention and writing talents to the topic of depression and pregnancy this week in the New York Times. However, a crucial part of providing good care to depressed pregnant women is to give them accurate information on the topic. In this sense, Andrew Solomon falls short.
Sir Robin Murray, a professor at the Institute of Psychiatry, Psychology, and Neuroscience in London, states that he ignored social factors that contribute to ‘schizophrenia’ for too long. He also reports that he neglected the negative effects antipsychotic medication has on the brain.
An anthropological look at the Global Mental Health (GMH) movement suggests several ethical problems and contradictions in its mission.
Effects of discontinuing SSRIs and SNRIs reported on an online forum indicate significant and long-lasting withdrawal symptoms.
A team in the Netherlands is currently investigating the effects of tapering off of antidepressants known as selective serotonin reuptake inhibitors (SSRIs) during pregnancy....
A new study finds that more than a third of Americans are taking prescription drugs that can cause depressive symptoms as a side-effect.
Antipsychotics are currently the predominant treatment for individuals diagnosed with schizophrenia, but there is an accumulating body of research that links the use of these drugs to structural abnormalities in the brain. A recent meta-analysis suggests that gray matter loss in the brain may depend on the dose and class of the antipsychotic.
"There is a need of a shift in investments in mental health, from focusing on 'chemical imbalances' to focusing on 'power imbalances' and inequalities"
A new study indicates that popular online resources do not accurately present the scientific evidence on the risks and benefits of antidepressants.
In my wildest dreams, I could never have imagined being drawn into a story of intrigue involving my own government’s efforts to hide, from the public, reports of psychiatric drugs associated with cases of murder, including homicides committed by youth on the drugs. But that is precisely the intrigue I now find myself enmeshed in.
Neuropsychological assessments reveal the cognitive, occupational, and social impact of polypharmacy in psychiatry.
A new study in JAMA Neurology finds that the use of antipsychotic drugs more than doubled the risk of death in patients with Parkinson’s...
Industry-funded continuing medical education (CME) influences physicians to prescribe more opioids, focus less on the consequences.
A new update to the NICE guideline for depression suggests providers discuss long-term, severe antidepressant withdrawal symptoms.
An article published this month in the journal BMC Psychiatry suggests that there is a lack of efficacy for SSRIs and that they significantly increase the risk of serious side effects.
Researchers, Jon Jureidini, Jay Amsterdam and Leemon McHenry, have taken a closer look at the data from a randomized control trial of citalopram (Celexa) that was ghostwritten and then used by the manufacturers to support claims of the drug’s efficacy and safety in the treatment of child and adolescent depression. To get the background on this story, we connected with Dr. Leemon McHenry, an investigator in this study and a lecturer in philosophy at California State University, Northridge.
Questionable research practices and poor reproducibility in electrical brain stimulation (EBS) studies.
Jürgen Margraf and Silvia Schneider, both well-known psychologists at the University of Bochum in Germany, claim that psychotropic drugs are no solution to mental...
This column is partly a report on the marketing of Abilify, the atypical antipsychotic that has become America’s best-selling drug. It’s also an appeal for advice and feedback from the RxISK and Mad in America communities, and a call for some brainstorming about strategy. The plans laid out by drugmakers Otsuka and Lundbeck for Abilify’s future, and the cooperation they’re getting from leading universities, are alarming enough to me that reporting on them seems inadequate. We need action, although I’m not sure exactly what kind.
A recent review, published in Neuroscience & Biobehavioral Reviews, challenges the dominant assumptions about the neurochemical and therapeutic effects of Selective Serotonin Reuptake Inhibitors...
Psychostimulant prescriptions have increased by 344% (from 2003 to 2015) for women of reproductive age (15-44 years old).
A new study found that prazosin was associated with increased insomnia and nightmares, and did not reduce suicidal thoughts.
The writings of Pies and his colleagues, I believe, provide a compelling case study of cognitive dissonance. Cognitive dissonance arises when people are presented with information that creates conflicted psychological states, challenging some belief they hold dear, and people typically resolve dissonant states by sifting through information in ways that protect their self-esteem and their financial interests. It is easy to see that process operating here.